• Shunsuke Saito, Taichi Sakaguchi, Shigeru Miyagawa, Hiroyuki Nishi, Yasushi Yoshikawa, Satsuki Fukushima, Takashi Daimon, and Yoshiki Sawa.
• Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
• J. Heart Lung Transplant. 2012 Aug 1;31(8):858-64.

BackgroundLong-term outcomes of a biventricular assist device (BiVAD) support are worse than those of an isolated left ventricular assist device (LVAD) support. This study evaluated our strategy for right heart failure using a temporary right VAD (RVAD) with an extracorporeal centrifugal pump.MethodsFrom January 2001 to December 2010, 108 patients underwent LVAD implantation at our institution and their clinical outcomes were studied.ResultsA temporary centrifugal RVAD was implanted in 26 patients. Multivariate logistic regression revealed pre-operative extracorporeal life support (odds ratio [OR], 37.0), central venous pressure (OR, 1.2), mean pulmonary artery pressure (OR, 0.9), and serum total bilirubin (OR, 1.4) were the risk factors for RVAD requirement. RVAD-off test was conducted, and 11 of the 26 patients showed significant recovery of right heart function and were eventually removed from RVAD support. The survival of patients with isolated LVAD was significantly better than those with a paracorporeal pulsatile BiVAD (80% vs 11% at 1 year, p < 0.001). However, there was no significant difference between the survival of patients who underwent isolated LVAD support and those who were initially implanted with temporary BiVAD but underwent the RVAD removal (80% vs 73% at 1 year, p = 0.827).ConclusionOur strategy with temporary RVAD for severe acute right heart failure was effective in selecting the patients who could be weaned from RVAD support. Patient survival was improved by avoiding the long-term support with a paracorporeal pulsatile BiVAD.Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

32 keywords...

hide…